Regeneron Pharmaceuticals, Inc.
REGN · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $14.3B | $14.2B | +1.0% |
| Operating income | $3.58B | $3.99B | −10.3% |
| Net income | $4.50B | $4.41B | +2.1% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Oct 30, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $5.12B | $3.75B | +36.3% |
| Operating income | $2.05B | $1.03B | +99.5% |
| Net income | $1.95B | $1.46B | +33.5% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Regeneron's revenue in FY2025?
- $14.3B in FY2025 (Fiscal year ended Dec 31, 2025), +1.0% vs $14.2B a year earlier, per its 10-K filed Feb 2026.
- Was Regeneron profitable in FY2025?
- Yes: net income was $4.50B and operating income $3.58B in FY2025.
- What was Regeneron's revenue in Q3 2026?
- $5.12B (+36.3% vs a year earlier), per its Form 10-Q filed Oct 30, 2026.